BrachytherapyPub Date : 2023-09-01DOI: 10.1016/j.brachy.2023.06.212
Juan Wang, Yansong Liang, Zezhou Liu, Hongtao Zhang
{"title":"PO111","authors":"Juan Wang, Yansong Liang, Zezhou Liu, Hongtao Zhang","doi":"10.1016/j.brachy.2023.06.212","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.212","url":null,"abstract":"There is no one-size-fits-all treatment decision for non-melanoma skin cancer (NMSC) in elderly patients, especially patients over 80 years old with multiple comorbidities. As a minimally invasive technology, iodine-125 seeds interstitial brachytherapy (BT) has been applied to solid tumors of the whole body, because it can offer a better dose distribution, which considered to be an effective, simple and safe alternative for local treatment of cancer. We aimed to explore its safety and efficacy for age 80 or older patient with early primary high-risk NMSC. As a retrospective and monocentric report, we collected 80+ year-old patients with early primary high-risk non-melanoma skin cancer treated by personalized iodine-125 seeds interstitial brachytherapy (PISI-BT) between December 2003 and May 2020. Survival status, efficacy, adverse effects (AEs), cosmetic result, cost were recorded (data cut-off, November 20st 2021). Results Only 9 patients met the criteria, median age was 86 (81-90), 5 of 9 were Eastern Cooperative Oncology Group (ECOG) 1, and each of them suffered from at least one comorbidity. After a median follow-up of 29.3 months (3-99), only 2 patients alive, 6 patients showed complete response (CR), 3 showed partial response(PR), and stable disease(SD), progressive disease(PD) were 0, respectively. No recurrences, disease persistence and AEs were detected during the follow-up and the death causes was irrelevant to NMSC. The cosmetic result of Excellent and Good were 2 and 4, 3 cannot be evaluated. The cost (included in the scope of medical insurance reimbursement) was acceptable. Conclusions PISI-BT could be an alternative in 80+ year-old patients with early primary high-risk NMSC. There is no one-size-fits-all treatment decision for non-melanoma skin cancer (NMSC) in elderly patients, especially patients over 80 years old with multiple comorbidities. As a minimally invasive technology, iodine-125 seeds interstitial brachytherapy (BT) has been applied to solid tumors of the whole body, because it can offer a better dose distribution, which considered to be an effective, simple and safe alternative for local treatment of cancer. We aimed to explore its safety and efficacy for age 80 or older patient with early primary high-risk NMSC. As a retrospective and monocentric report, we collected 80+ year-old patients with early primary high-risk non-melanoma skin cancer treated by personalized iodine-125 seeds interstitial brachytherapy (PISI-BT) between December 2003 and May 2020. Survival status, efficacy, adverse effects (AEs), cosmetic result, cost were recorded (data cut-off, November 20st 2021). Only 9 patients met the criteria, median age was 86 (81-90), 5 of 9 were Eastern Cooperative Oncology Group (ECOG) 1, and each of them suffered from at least one comorbidity. After a median follow-up of 29.3 months (3-99), only 2 patients alive, 6 patients showed complete response (CR), 3 showed partial response(PR), and stable disease(SD), progressi","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BrachytherapyPub Date : 2023-09-01DOI: 10.1016/j.brachy.2023.06.174
Wiwatchai Sittiwong, Pittaya Dankulchai
{"title":"PO73","authors":"Wiwatchai Sittiwong, Pittaya Dankulchai","doi":"10.1016/j.brachy.2023.06.174","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.174","url":null,"abstract":"Purpose To identify a predictive factor associated with local recurrence in prostate cancer patients receiving HDR brachytherapy. Materials and Methods Localized, non-metastatic prostate cancer patients who were treated with brachytherapy with or without external beam radiation (EBRT) between January 2015 to December 2021 were retrospectively reviewed. HDR monotherapy was prescribed at 19 Gy to prostate while HDR brachytherapy was prescribed at 15 Gy to prostate after EBRT of 45-50 Gy to whole pelvis. Factors to identify a predictor of local recurrence included prostate volume, dominant intraprostatic lesion (DIL) volume, PSA density and DIL-concentrated PSA (DILcPSA). DILcPSA is defined as the PSA density within the area of DIL volume which can be calculated by PSA density multiplied by DIL volume. Baseline patient characteristics and tumor characteristics were reported. Univariate and multivariate analysis were performed to identify factors associated local recurrence by using Cox's regression analysis. Results 32 patients with the median follow up time of 59.2 months were included. The median age of patients was 70 years. Most patients were categorized as unfavorable to very high risk (19 patients, 59.4%); however, most common grade group was grade group 2 (14 patients, 43.7%). Most patients received androgen deprivation therapy (ADT) either by medication or surgical castration (25 patients, 78.1%). The proportion of patients underwent HDR brachytherapy as monotherapy (18 patients, 56.2%) was similar to as a boost (14 patients, 43.8%). For tumor characteristics, most of DILs were located at peripheral zone (28 patients, 87.5%). Median DIL volume and prostate volume were 1.13 ml (95%CI 0.78 to 1.48), and 39.4 ml (95%CI 31.38 to 47.42), respectively. Median PSA density and DILcPSA were 0.30 (95%CI 0.12 to 0.48) and 0.33 (95%CI 0.15 to 0.51), respectively. There were 9 patients developed local recurrence. The rate of 5-year local recurrence-free survival was 68.5%. Among factors selected to predict local recurrence, DILcPSA was found to be significantly associated with local recurrence for both univariate and multivariate Cox's regression analysis with HR of 2.10 (95%CI 1.12 to 27.67) p=0.035 and 2.06 (95%CI 1.09 to 27.41) p 0.039, respectively. Prostate volume, DIL volume and PSA density were found no significant correlation with local recurrence. Conclusions DILcPSA could be a potential predictive factor to predict local recurrence in prostate cancer patients receiving HDR brachytherapy. To identify a predictive factor associated with local recurrence in prostate cancer patients receiving HDR brachytherapy. Localized, non-metastatic prostate cancer patients who were treated with brachytherapy with or without external beam radiation (EBRT) between January 2015 to December 2021 were retrospectively reviewed. HDR monotherapy was prescribed at 19 Gy to prostate while HDR brachytherapy was prescribed at 15 Gy to prostate after EBRT of 45-50 Gy to wh","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"25 2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BrachytherapyPub Date : 2023-09-01DOI: 10.1016/j.brachy.2023.06.127
Pooja Venkatesh, Juhi Purswani, Nicholas Colangelo, Sofia Perez Otero, Nicole Hindman, Stella Lymberis
{"title":"PO26","authors":"Pooja Venkatesh, Juhi Purswani, Nicholas Colangelo, Sofia Perez Otero, Nicole Hindman, Stella Lymberis","doi":"10.1016/j.brachy.2023.06.127","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.127","url":null,"abstract":"Purpose Radiation toxicity to female erectile tissue, specifically the bulboclitoral apparatus, has not been previously investigated. This retrospective cohort study aims to demonstrate the feasibility of contouring the bulboclitoris (BC) and evaluate dose received by the BC in patients who underwent interstitial gynecologic brachytherapy for tumors involving the lower vagina and periurethral region. Materials and Methods Patients were treated with HDR brachytherapy between the years 2017 and 2022. All patients underwent IMRT external beam radiotherapy (EBRT) to the pelvis and bilateral inguinal region (45 Gy in 25 fractions) followed by High Dose Rate Ir-192 interstitial brachytherapy using the CT/MR M.A.C. Interstitial Gyn Template in 5 fractions for a total dose of 25 Gy (range, 22.5 - 27.5 Gy). The bulboclitoris (BC) was contoured retrospectively by a radiation oncologist and a pelvic radiologist using T2 MRI sequences fused to the pre-treatment and brachytherapy CT simulation. Superiorly, the BC was defined as inferior to the pubic symphysis and attached to the suspensory ligament of the clitoris. Laterally, the crura extend on either side of the corpus. Inferiorly, the vestibular bulbs flank the urethra and vagina on either side and do not extend posteriorly beyond the vagina. A representative contour of the bulboclitoral apparatus is depicted in Figure 1. Dosimetric data for the BC were calculated using EQD2 assuming an alpha-beta ratio of 3 Gy. Median follow up, local control, and vaginal morbidity using CTCAE version 4.0 for vaginal stenosis and pain scoring of the BC was evaluated. Results Patients had a median age of 65 years (range, 49-73). Three of the five patients had a diagnosis of squamous cell carcinoma of the vagina, one patient had recurrent cervical cancer in the vagina, and one patient had endometrioid adenocarcinoma involving the vagina. All tumors were located in the lower vagina, near the BC and urethra. The high-risk clinical target volume (HR-CTV), bladder, rectum, and urethra were contoured on patient imaging during initial treatment planning. Mean D90 of the HR-CTV was 79.82 Gy (range, 72.2-89.9 Gy), mean D2cc to the bladder was 66.54 Gy (range, 50.0-87.2 Gy), mean D2cc to the rectum was 60.9 Gy (range, 46.9-72.9), and mean D0.1cc to the urethra was 79.28 Gy (range, 53.9-93 Gy). At a median follow up of 19.6 months, all patients had a complete local response. One patient had systemic progression and died of metastatic disease. The mean pre-treatment volume of the bulboclitoris was 16.6 cc (range, 11.9 - 20.9 cc) and at brachytherapy was 12.66 cc (range, 7.3 - 22.1 cc). The mean IMRT dose to the BC was 45.87 Gy (range, 44.79 - 46.66 Gy) and mean HDR dose was 14.02 Gy (range, 11.23 - 18.88 Gy). Assuming an alpha-beta ratio of 3 Gy, mean bulboclitoral D90 EQD2 was 62.93 Gy (range of 58.72 to 67.22 Gy). In the acute period, all patients reported severe pain in the clitoral glans region and dysuria that completely resolved","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"60 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BrachytherapyPub Date : 2023-09-01DOI: 10.1016/j.brachy.2023.06.184
Christopher Jason Tien, Emily Draeger, Fada Guan, David J. Carlson, Zhe Jay Chen
{"title":"PO83","authors":"Christopher Jason Tien, Emily Draeger, Fada Guan, David J. Carlson, Zhe Jay Chen","doi":"10.1016/j.brachy.2023.06.184","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.184","url":null,"abstract":"Purpose In order to develop a robust universal model which can accurately predict tumor control probability (TCP), it is necessary to first explore the sensitivity of the model on its input radiobiological parameters. We propose a methodology to derive population-averaged values of TCP based on a computational “clinical trial” with an enrollment of virtual patients orders of magnitude larger than physically-achievable cohort sizes (∼1 million), each with precisely-known radiobiological parameter values. Materials and Methods Each virtual patient was randomly assigned α and α/β values following a randomized distribution based on a previous study by Wang et al, endorsed by AAPM TG137 and TG265: α to a log-normal distribution function with mean (µ) of 0.15 Gy-1 and standard deviation (σ) of 0.04 Gy-1; α/β to a Gaussian function with µ=3.1 Gy and σ= 0.5 Gy; the initial clonogenic population was a fixed value of 1.6 x 106 (low-risk patient cohort). Next, after establishing the cohort, the TCP was calculated for each patient using the linear-quadratic (LQ) model assuming Poisson statistics for a range of doses from 0 to 140 Gy. The fractional TCP value was compared against a random number generator value to ultimately determine the binary patient outcome (i.e. TCP or fail). This process was repeated for each patient in the trial and the final population-based TCP was calculated by the ratio of successes to the number of patients in the trial. A series of new trials was created with one million patients to test α and α/β dependence with intentional variations in α or α/β values for α values from 0.7 to 0.23 Gy-1 and α/β values from 1.5 to 5.0 Gy. Results A series of 11 TCP curves was generated. For each curve, one million patients were created and assigned values of α, α/β. For the reference cohort using both the Gaussian and log-normal functions, the TCP90% and TCP50% were 89.4 and 68.9 Gy. With only a fixed log-normal α function, TCP90% was 70.3, 84.3, 89.4, 93.1, 101 Gy and TCP50% was 56.4, 65.9, 69.6, 71.8, 77.7 Gy for α/β=1.5, 2.6, 3.1, 3.6, 5 Gy, respectively. With only a fixed Gaussian α/β function, TCP90% was 126.1, 92.3, 74.0, 62.3 53.5 and TCP50% was 114.3, 89.8, 67.4, 56.4, 48.3 Gy for α=0.07, 0.11, 0.15, 0.19, 0.23 Gy-1, respectively. As illustrated in the Figure, larger values of α or smaller α/β ratios shift the TCP curve to lower TCP90% and TCP50%. Additionally, choosing a distribution of α values centered on 0.15 Gy-1 rather than a fixed α=0.15 Gy-1 significantly flattens the slope of the TCP curve, while using a distribution of α/β values produced indistinguishable TCP curves. Conclusions By leveraging the Law of Large Numbers and raw computing power, we were able to create multiple heterogeneous cohorts each containing 1 million virtual patients to generate realistic TCP curves based on previously published distributions of plausible α and α/β values, such as those endorsed by AAPM TG137 and TG265. This virtual clinical trial was able ","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"43 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BrachytherapyPub Date : 2023-09-01DOI: 10.1016/j.brachy.2023.06.109
Jill Bennett, Cédric Bélanger, Philippe Chatigny, Luc Beaulieu, Alexandra Rink
{"title":"PO08","authors":"Jill Bennett, Cédric Bélanger, Philippe Chatigny, Luc Beaulieu, Alexandra Rink","doi":"10.1016/j.brachy.2023.06.109","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.109","url":null,"abstract":"Purpose Brachytherapy (BT) is an essential pillar in the treatment of cervical cancer. One method of gynecological (GYN) BT uses a transperineal catheter-guiding template in combination with an intrauterine (IU) tandem. Typically, catheter locations are decided using pre-BT imaging, and radiation treatment plans are then determined based on imaging taken after catheter insertion. Due to changes in patient anatomy once the IU tandem is inserted, this approach can lead to suboptimal tumor coverage, and often unused catheters, which contribute to increased implantation time, unnecessary tissue injury, and increased risk of bleeds. Images taken after insertion of the Template and APPlicator (post-TAPP) used in conjunction with a simple geometric catheter placement optimization algorithm may result in fewer unused catheters with better or equivalent dosimetry. In previous studies on prostate BT, the use of a Centroidal Voronoi Tessellation (CVT) algorithm for catheter optimization led to equivalent or superior treatment plans using fewer IS catheters compared to clinical cases. This work aims to verify these findings for cervical cancer BT. Materials and Methods Cases of locally advanced cervical cancer treated from 2016 to 2020 using IS BT with a Syed Neblett template were selected (N=12). Post-insertion imaging with target, organ-at-risk (OAR), and clinical catheter delineations were retrieved from the first BT fraction for each patient. CVT was used to simulate post-TAPP optimized catheters for each case by uniformly distributing catheters throughout a 2D projection of the target volume. The number of catheters in the CVT arrangement was equal to the number of catheters in the clinical implant, or the number of available template positions in the CVT planning region (defined as the high risk clinical target volume [HR-CTV] minus OARs projected onto the template plane), whichever number was lower. Treatment plans were then manually generated by a single expert for both the CVT and clinical catheter arrangements. Plan acceptability was evaluated via compliance with the EMBRACE-II dose-volume histogram limits in equieffective dose in 2 Gy per fraction (EQD2). Measures of dose inhomogeneity (%V150HR-CTV and %V200HR-CTV) were also recorded. Results The mean time for catheter optimization using CVT was 11.49 s. In all cases but 1, the CVT arrangements led to improved or EMBRACE-II compliant treatment plans with as many or fewer inserted catheters compared to the clinical cases (Figure 1). An increase in mean D90HR-CTV, D98HR-CTV, and D98IR-CTV was observed in the CVT group compared to the clinical group, as well as a statistically significant 2.2 Gy increase in mean D98GTVres (p < 0.05). A 2.2% increase in mean %V150HR-CTV was observed in the CVT group (p < 0.05). The mean number of unused catheters decreased from 4 in the clinical plans to 0 in the CVT plans (p < 0.001), and the acceptability rate increased from 50% with clinical catheters to 66.67% wit","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BrachytherapyPub Date : 2023-09-01DOI: 10.1016/j.brachy.2023.06.155
Joel Poder, Philip Turner, Yaw Chin, Nadine Beydoun, Ese Enari, Andrew Howie
{"title":"PO54","authors":"Joel Poder, Philip Turner, Yaw Chin, Nadine Beydoun, Ese Enari, Andrew Howie","doi":"10.1016/j.brachy.2023.06.155","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.155","url":null,"abstract":"Purpose Low dose rate (LDR) brachytherapy has been proven to be an effective modality for monotherapy treatment of low-intermediate risk prostate cancer. The most commonly used treatment workflow follows a pre-planning approach utilising trans-rectal ultrasound (TRUS) images acquired under sedation, or nomogram planning based on manual measurements of prostate volume and dimensions. This study presents an alternative approach in which diagnostic magnetic resonance images (MRI) are used for the purpose of treatment planning, eliminating the necessity of an additional operating theatre procedure for the purposes of treatment planning, whilst tailoring the plan specifically to the patient's anatomy. Materials and Methods A retrospective study (n=10) was performed comparing the MRI and TRUS pre-planned approaches. The MRI pre-planned approach was retrospectively simulated by creating an LDR brachytherapy plan on diagnostic MR images using the Varian Variseed (v9.0.03) brachytherapy treatment planning system according to local protocols. This plan was then copied onto previously obtained TRUS planning images for the same patient. TRUS and MRI pre-plans were compared by evaluating plan quality metrics such as: the volume of the prostate receiving 100% (V100%), 150% (V150%), and 200% (V200%), dose to 90% of the prostate volume (D90%), as well as the rectum V100%, and urethra V125%. The prescription dose used in each plan was 145 Gy. The number of needles and number of seeds used in each approach was also compared. Statistical significance was tested for via the paired two sides t-test (p < 0.05). A prospective comparison study of operating theatre time usage is ongoing. Results Retrospective comparison of the planning approaches showed no statistically significant differences in plan quality metrics, apart from for the rectum V100%. The TRUS and MRI pre-planned approaches achieved an average rectum V100% of 0.14 cc and 0.33 cc (p = 0.008), respectively. Both approaches easily met the clinical constraint of rectum V100% < 1 cc, and thus the difference between the techniques was not clinically significant. All other plan quality metrics met departmentally defined clinical planning constraints for both the TRUS and MRI planned technique. Preliminary results comparing operating theatre time usage has shown significant time savings using the MRI-pre planning technique. Conclusions The MRI pre-planned approach for LDR prostate brachytherapy has been shown to achieve dosimetrically equivalent plans to TRUS based pre-plans, using less operating theatre resources. This technique is a safe and effective form of LDR prostate brachytherapy treatment planning for eligible patients. Low dose rate (LDR) brachytherapy has been proven to be an effective modality for monotherapy treatment of low-intermediate risk prostate cancer. The most commonly used treatment workflow follows a pre-planning approach utilising trans-rectal ultrasound (TRUS) images acquired under sedati","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"42 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
求助内容：
应助结果提醒方式：